Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| E1609 | ECOG | A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma<br> | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E1899 | ECOG | Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) versus Docetaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with a Rising PSA after Hormonal Therapy for Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed | |
| E1900 | ECOG | A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-<br>Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E1910 | ECOG | A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E1912 | ECOG | A Randomized Phase III Study of Ibrutinib (PCI- 32765)-based Therapy vs Standard Fludarabine; Cyclophosphamide; and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E1A00 | ECOG | A Randomized Phase III Trial of Thalidomide (NSC #66847) Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma | Adult CIRB - Late Phase Emphasis | Completed | |
| E1A05 | ECOG | Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) - Lenalidomide (Revlimid) - Dexamethasone (VRD) versus Bortezomib (Velcade) - Dexamethasone (VD) for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen | Adult CIRB - Late Phase Emphasis | Completed | |
| E1A06 | ECOG | An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan; Prednisone and Thalidomide (MPT) Versus Melphalan; Prednisone and Lenalidomide (Revlimid TM) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E1A11 | ECOG | Randomized Phase III Trial of Bortezomib; LENalidomide and Dexamethasone (VRd) Versus Carfilzomib; Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| E1Q11 | ECOG | EROS: Engendering Reproductive Health within Oncologic Survivorship | Cancer Prevention and Control CIRB | Available to Open |